Loading...
•
Dec 31, 2024
COMPASS Q4 2024 Earnings Report
Reported financial results for Q4 2024 and provided a business update.
Key Takeaways
Compass Pathways reported a net loss of $43.3 million for the quarter ended December 31, 2024. The company's cash and cash equivalents were $165.1 million as of December 31, 2024. Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025.
Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025
Phase 3 COMP006 in TRD is on track for 26-week data in second half of 2026
Cash position of $165.1 million at December 31, 2024; additional $150 million gross cash proceeds raised in January 2025
Design of late-stage clinical program in patients with post-traumatic stress disorder (PTSD) is underway
Forward Guidance
Full year 2025 net cash used in operating activities is expected to be in the range of $120 million to $145 million. The cash position at February 27, 2025 is expected to be sufficient to fund operating expenses and capital expenditure requirements at least through the planned 26-week data read-out from the COMP006 study, which is expected in the second half of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...